![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Tracking Information | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Received Date † | March 8, 2004 | ||||||||||||||||
Last Updated Date | May 13, 2009 | ||||||||||||||||
Start Date † | January 2004 | ||||||||||||||||
Current Primary Outcome Measures † |
Time to first skeletal related event [ Designated as safety issue: No ] | ||||||||||||||||
Original Primary Outcome Measures † | Same as current | ||||||||||||||||
Change History | Complete list of historical versions of study NCT00079001 on ClinicalTrials.gov Archive Site | ||||||||||||||||
Current Secondary Outcome Measures † |
|
||||||||||||||||
Original Secondary Outcome Measures † |
|
||||||||||||||||
Descriptive Information | |||||||||||||||||
Brief Title † | Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases | ||||||||||||||||
Official Title † | A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone | ||||||||||||||||
Brief Summary | RATIONALE: Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy. It is not yet known whether treatment with zoledronate is effective in preventing bone-related events in patients who have prostate cancer and bone metastases. PURPOSE: This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases. |
||||||||||||||||
Detailed Description | OBJECTIVES: Primary
Secondary
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study followed by an open-label study. Patients are stratified according to ECOG performance status (0-1 vs 2), prior skeletal-related event (no vs yes), and serum alkaline phosphatase (< upper limit of normal [ULN] vs ≥ ULN). Patients are randomized to 1 of 2 treatment arms.
Patients progressing to androgen-independent prostate cancer proceed to open-label therapy comprising zoledronate IV over 15 minutes on day 1. Courses repeat every 3 weeks in the absence of disease progression or a skeletal-related event. Patients are followed periodically for approximately 10 years after randomization. PROJECTED ACCRUAL: A total of 680 patients (340 per treatment arm) will be accrued for this study within 4 years. |
||||||||||||||||
Study Phase | Phase III | ||||||||||||||||
Study Type † | Interventional | ||||||||||||||||
Study Design † | Treatment, Randomized, Open Label, Placebo Control | ||||||||||||||||
Condition † |
|
||||||||||||||||
Intervention † |
|
||||||||||||||||
Study Arms / Comparison Groups |
|
||||||||||||||||
Publications * | |||||||||||||||||
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||||||||||
Recruitment Information | |||||||||||||||||
Recruitment Status † | Recruiting | ||||||||||||||||
Estimated Enrollment † | 680 | ||||||||||||||||
Completion Date | |||||||||||||||||
Estimated Primary Completion Date | January 2008 (final data collection date for primary outcome measure) | ||||||||||||||||
Eligibility Criteria † | DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
|
||||||||||||||||
Gender | Male | ||||||||||||||||
Ages | 18 Years and older | ||||||||||||||||
Accepts Healthy Volunteers | No | ||||||||||||||||
Contacts †† | |||||||||||||||||
Location Countries † | United States, Canada | ||||||||||||||||
Expanded Access Status | |||||||||||||||||
Administrative Information | |||||||||||||||||
NCT ID † | NCT00079001 | ||||||||||||||||
Responsible Party | Richard L. Schilsky, Cancer and Leukemia Group B | ||||||||||||||||
Secondary IDs †† | CALGB-90202, ECOG-CALGB-90202, SWOG-CALGB-90202, CAN-NCIC-PRC2 | ||||||||||||||||
Study Sponsor † | Cancer and Leukemia Group B | ||||||||||||||||
Collaborators †† |
|
||||||||||||||||
Investigators † |
|
||||||||||||||||
Information Provided By | National Cancer Institute (NCI) | ||||||||||||||||
Verification Date | May 2009 | ||||||||||||||||
† Required WHO trial registration data element. †† WHO trial registration data element that is required only if it exists. |